Sage Therapeutics, Inc. (NASDAQ:SAGE) Rating Changes as of Feb 14, 2019

Sage Therapeutics, Inc. (NASDAQ:SAGE) Corporate Logo
Big Money Sentiment decreased to 1.15 in Q3 2018. It has change of 0.56, from 2018Q2’s 1.71. The ratio dived due to Sage Therapeutics, Inc. positioning: 23 sold and 73 reduced. 43 funds took stakes and 67 increased stakes. Investors holded 46.94 million in 2018Q2 but now own 46.64 million shares or 0.64% less.
Oppenheimer Asset Management reported 4,319 shs. Mutual Of America Capital Mgmt Ltd stated it has 15,836 shs. Polar Cap Llp has 0.04% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Utah Retirement Systems invested in 0.02% or 8,400 shs. Tocqueville Asset L P reported 0.15% stake. Wells Fargo Company Mn stated it has 388,706 shs. Jennison Assocs Limited Liability accumulated 810,224 shs or 0.11% of the stock. Stevens Cap Management L P holds 0.14% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 26,177 shs. Victory Cap Management Inc holds 0.12% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 420,735 shs. State Of Wisconsin Invest Board reported 8,715 shs or 0% of all its holdings. 11,727 were reported by Cubist Systematic Strategies Limited Liability Co. Sg Americas Secs Ltd Liability owns 2,575 shs. 329,837 are held by Ameriprise Financial. Aperio Ltd Co holds 0% or 2,282 shs. Strs Ohio invested 0.09% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE).

Sage Therapeutics, Inc. had 2 insider sales and 0 buys since January 23, 2019. This’s net activity of $4.45 million. Kanes Stephen sold $3.44M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Friday, February 8.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

In total 3 analysts cover Sage Therapeutics (NASDAQ:SAGE). “Buy” rating has 2, “Sell” are 1, while 0 are “Hold”. (NASDAQ:SAGE) has 67% bullish analysts. 4 are the (NASDAQ:SAGE)’s ratings reports on Feb 14, 2019 according to StockzIntelligence Inc. On Wednesday, December 19 the firm earned “Overweight” rating by Morgan Stanley. On Thursday, October 11 the rating was maintained by Morgan Stanley with “Overweight”. The company rating was maintained by RBC Capital Markets on Monday, November 5. Listed here are Sage Therapeutics, Inc. (NASDAQ:SAGE) PTs and latest ratings.

19/12/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $230 New Target: $213 Maintain
13/11/2018 Broker: Leerink Swann Rating: Underperform New Target: $80 Initiates Coverage On
05/11/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $259 New Target: $261 Maintain
11/10/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $228 New Target: $230 Maintain

Ticker’s shares touched $157.63 during the last trading session after 2.43% change.Currently Sage Therapeutics, Inc. is uptrending after 17.03% change in last February 14, 2018. SAGE has 8 shares volume. SAGE outperformed by 17.03% the S&P 500.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders.The firm is valued at $7.39 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD).Currently it has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

For more Sage Therapeutics, Inc. (NASDAQ:SAGE) news released recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Businesswire.com. The titles are as follows: “Sage Group to sell its U.S. payroll outsourcing unit for $100 million – Nasdaq” released on January 15, 2019, “Creative Dining Services Leverages Sage to Increase Cash Flow by $760000 – Nasdaq” on January 22, 2019, “UK Stocks-Factors to watch on Jan 18 – Nasdaq” with a publish date: January 18, 2019, “SAGE Crosses Above Key Moving Average Level – Nasdaq” and the last “Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors – Business Wire” with publication date: January 23, 2019.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.